Perrigo Ends 2017 As It Started: Earnings Results Delayed
This article was originally published in The Pink Sheet & The Rose Sheet
You may also be interested in...
Hendrickson recounts Perrigo's strategies to right the ship after a hole in earnings opened from investing in a European consumer health business and operating API and dietary supplement divisions and as pricing pressures on generic drugs took some wind out of its revenue sails.
Perrigo named German packaging firm executive Uwe Rohrhoff as CEO, replacing John Hendrickson, effective Jan. 15. The former head of Gerresheimer will bring experience leading a global business that included 36 manufacturing facilities across 14 countries and sales of $1.7bn.
Perrigo's third-quarter launch of private label Nexium24HR was primary contributor of $13m in new product sales in North America.